Keros Therapeutics (KROS) Invested Capital (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Invested Capital data on file, last reported at $303.1 million in Q4 2025.

• For the quarter ending Q4 2025, Invested Capital fell 46.96% year-over-year to $303.1 million; the trailing twelve-month figure through Dec 2025 stood at $303.1 million (down 46.96% YoY), and the FY2025 full-year result was $303.1 million, down 46.96% from the prior year.
• Invested Capital for Q4 2025 stood at $303.1 million, down from $703.6 million in the prior quarter.
• Across five years, Invested Capital topped out at $728.9 million in Q1 2025 and bottomed at $211.2 million in Q2 2022.
• The 5-year median for Invested Capital is $314.7 million (2023), against an average of $381.5 million.
• The widest annual swing landed in 2021, when Invested Capital surged 1098.8%; it then sank 46.96% in 2025.
• A 5-year view of Invested Capital shows it stood at $243.2 million in 2021, then rose by 14.08% to $277.4 million in 2022, then climbed by 19.75% to $332.2 million in 2023, then surged by 72.04% to $571.6 million in 2024, then sank by 46.96% to $303.1 million in 2025.
• The last three Invested Capital figures came in at $303.1 million (Q4 2025), $703.6 million (Q3 2025), and $706.7 million (Q2 2025), per Business Quant data.

Peer Comparison